Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop multi-payload antibody-drug conjugates. Analysts weighed in on whether Legend Biotech and BeiGene could become buyout targets in …